Literature DB >> 11816828

Drug-induced infiltrative lung disease.

P H Camus1, P Foucher, P H Bonniaud, K Ask.   

Abstract

An increasing number of drugs are recognized to induce distinctive patterns of infiltrative lung disease (ILD), ranging from benign infiltrates to life-threatening adult respiratory distress syndromes. In addition to drugs, biomolecules such as proteins and cytokines, and medicinal plants are also capable of inducing respiratory disease, some being severe and/or irreversible. For several reasons it is difficult to estimate the exact frequency of drug-induced infiltrative lung disease (DI-ILD). The risk for DI-ILD and the clinical patterns vary depending on a variety of host and drug factors. Although establishing the diagnosis is often difficult, systematic evaluation of the possible role of almost any kind of drugs in ILD is warranted, as stopping a drug may favourably influence prognosis. However, prognosis depends on the drug and the type of DI-ILD. Corticosteroids may suppress the inflammatory reaction, but for many drugs, proof of the effect of corticosteroids is lacking. Advances in prevention and prediction are needed. A user-friendly database of respiratory adverse drug reactions was made available on the web, to provide quick information in this area.

Entities:  

Mesh:

Year:  2001        PMID: 11816828

Source DB:  PubMed          Journal:  Eur Respir J Suppl        ISSN: 0904-1850


  21 in total

1.  Clarithromycin and pulmonary infiltration with eosinophilia.

Authors:  Claudio Terzano; Angelo Petroianni
Journal:  BMJ       Date:  2003-06-21

2.  A puzzling pneumonia in a young immunosuppressed man.

Authors:  Udana Subodhika Ratnapala; Alim Yucel-Finn; David Walbaum; Owen Dempsey
Journal:  BMJ Case Rep       Date:  2018-04-17

3.  Prospective evaluation of drug-induced lung toxicity with high-resolution CT and transbronchial biopsy.

Authors:  S Piciucchi; M Romagnoli; M Chilosi; C Bigliazzi; A Dubini; B Beomonte Zobel; G Gavelli; A Carloni; V Poletti
Journal:  Radiol Med       Date:  2010-12-03       Impact factor: 3.469

4.  Eosinophilic infiltrate in a patient with severe Legionella pneumonia as a levofloxacin-related complication: a case report.

Authors:  Nicola Facciolongo; Francesco Menzella; Claudia Castagnetti; Alberto Cavazza; Roberto Piro; Cristiano Carbonelli; Luigi Zucchi
Journal:  J Med Case Rep       Date:  2010-11-11

5.  [Pulmonary infiltrates with blood eosinophilia in a 62-year-old patient].

Authors:  M Kohlhäufl; N Weber; A Morresi-Hauf; D Geiger; H Raith; K Häussinger
Journal:  Internist (Berl)       Date:  2003-08       Impact factor: 0.743

6.  Interstitial pneumonia associated with neoadjuvant chemotherapy in breast cancer.

Authors:  Hidemi Kawajiri; Tsutomu Takashima; Naoyoshi Onoda; Shinichiro Kashiwagi; Tetsurou Ishikawa; Kosei Hirakawa
Journal:  Mol Clin Oncol       Date:  2013-03-05

7.  Pulmonary toxicity in patients receiving docetaxel chemotherapy.

Authors:  Perran F Yumuk; Umut Kefeli; Berrin Ceyhan; Faysal Dane; Basak T Eroglu; Mahmut Gumus; Devrim Cabuk; Gul Basaran; Ufuk Abacioglu; Nazım S Turhal
Journal:  Med Oncol       Date:  2009-12-25       Impact factor: 3.064

8.  Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer.

Authors:  Omalkhair Abulkhair; Wael El Melouk
Journal:  Case Rep Oncol       Date:  2011-04-02

9.  Acute lung affection in an endurance-trained man under amiodarone medication.

Authors:  Stephan Walterspacher; Wolfram Windisch; Gernot Zissel; Bernward Saurbier; Stephan Sorichter
Journal:  Ger Med Sci       Date:  2005-06-01

Review 10.  Interstitial lung disease associated with drug therapy.

Authors:  P Camus; S Kudoh; M Ebina
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.